Pattern of Phenotypic Expression According to FAB Subtypes
| . | AML-M0* . | AML-M1 . | AML-M2 . | AML-M3 . | AML-M4 . | AML-M5 . | P Value . |
|---|---|---|---|---|---|---|---|
| HLA-DR+(%) | 22 (88) | 47 (87) | 54 (91) | 2 (7) | 48 (94) | 48 (96) | <.001 |
| CD34+(%) | 24 (96) | 38 (79) | 36 (71) | 4 (14) | 32 (71) | 23 (47) | <.001 |
| TdT+(%) | 17 (68) | 18 (35) | 5 (9) | 0 (0) | 11 (22) | 11 (22) | <.001 |
| C-kit+(%) | 7 (58) | 12 (75) | 11 (65) | 1 (14) | 14 (64) | 11 (33) | .014 |
| CD13+(%) | 17 (68) | 51 (94) | 53 (90) | 27 (93) | 48 (94) | 49 (96) | .002 |
| CD33+(%) | 16 (64) | 45 (83) | 56 (95) | 29 (100) | 51 (100) | 50 (98) | <.001 |
| CD14+(%) | 7 (28) | 8 (15) | 21 (36) | 13 (45) | 46 (90) | 44 (86) | <.001 |
| CD15+(%) | 5 (20) | 21 (39) | 48 (81) | 13 (45) | 39 (76) | 37 (72) | <.001 |
| CD11b+(%) | 9 (45) | 10 (26) | 19 (43) | 3 (13) | 25 (73) | 32 (82) | <.001 |
| CD11c+(%) | 5 (28) | 9 (33) | 16 (50) | 0 (0) | 17 (59) | 29 (72) | <.001 |
| CD2+(%) | 3 (12) | 4 (7) | 9 (15) | 9 (31) | 10 (20) | 11 (22) | NS |
| CD4+(%) | 5 (31) | 2 (8) | 4 (10) | 2 (12) | 10 (30) | 16 (37) | .014 |
| CD5+(%) | 2 (10) | 2 (8) | 2 (6) | 2 (13) | 2 (6) | 6 (14) | NS |
| CD7+(%) | 8 (32) | 22 (41) | 15 (25) | 2 (7) | 13 (25) | 24 (48) | .003 |
| CD10+(%) | 3 (12) | 3 (6) | 4 (7) | 0 (0) | 3 (6) | 6 (12) | NS |
| CD19+(%) | 2 (8) | 5 (9) | 5 (8) | 7 (3) | 3 (6) | 3 (6) | NS |
| GP-170+(%) | 6 (37) | 17 (49) | 22 (58) | 4 (20) | 17 (44) | 29 (64) | .020 |
| CD33+/CD13+(%) | 12 (48) | 43 (80) | 50 (85) | 27 (93) | 48 (94) | 48 (94) | <.001 |
| CD33−/CD13+(%) | 5 (20) | 8 (15) | 3 (5) | 0 (0) | 0 (0) | 1 (2) | <.001 |
| CD33+/CD13−(%) | 4 (16) | 4 (16) | 6 (10) | 2 (7) | 3 (6) | 2 (4) | <.001 |
| CD33−/CD13−(%) | 4 (16) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | <.001 |
| . | AML-M0* . | AML-M1 . | AML-M2 . | AML-M3 . | AML-M4 . | AML-M5 . | P Value . |
|---|---|---|---|---|---|---|---|
| HLA-DR+(%) | 22 (88) | 47 (87) | 54 (91) | 2 (7) | 48 (94) | 48 (96) | <.001 |
| CD34+(%) | 24 (96) | 38 (79) | 36 (71) | 4 (14) | 32 (71) | 23 (47) | <.001 |
| TdT+(%) | 17 (68) | 18 (35) | 5 (9) | 0 (0) | 11 (22) | 11 (22) | <.001 |
| C-kit+(%) | 7 (58) | 12 (75) | 11 (65) | 1 (14) | 14 (64) | 11 (33) | .014 |
| CD13+(%) | 17 (68) | 51 (94) | 53 (90) | 27 (93) | 48 (94) | 49 (96) | .002 |
| CD33+(%) | 16 (64) | 45 (83) | 56 (95) | 29 (100) | 51 (100) | 50 (98) | <.001 |
| CD14+(%) | 7 (28) | 8 (15) | 21 (36) | 13 (45) | 46 (90) | 44 (86) | <.001 |
| CD15+(%) | 5 (20) | 21 (39) | 48 (81) | 13 (45) | 39 (76) | 37 (72) | <.001 |
| CD11b+(%) | 9 (45) | 10 (26) | 19 (43) | 3 (13) | 25 (73) | 32 (82) | <.001 |
| CD11c+(%) | 5 (28) | 9 (33) | 16 (50) | 0 (0) | 17 (59) | 29 (72) | <.001 |
| CD2+(%) | 3 (12) | 4 (7) | 9 (15) | 9 (31) | 10 (20) | 11 (22) | NS |
| CD4+(%) | 5 (31) | 2 (8) | 4 (10) | 2 (12) | 10 (30) | 16 (37) | .014 |
| CD5+(%) | 2 (10) | 2 (8) | 2 (6) | 2 (13) | 2 (6) | 6 (14) | NS |
| CD7+(%) | 8 (32) | 22 (41) | 15 (25) | 2 (7) | 13 (25) | 24 (48) | .003 |
| CD10+(%) | 3 (12) | 3 (6) | 4 (7) | 0 (0) | 3 (6) | 6 (12) | NS |
| CD19+(%) | 2 (8) | 5 (9) | 5 (8) | 7 (3) | 3 (6) | 3 (6) | NS |
| GP-170+(%) | 6 (37) | 17 (49) | 22 (58) | 4 (20) | 17 (44) | 29 (64) | .020 |
| CD33+/CD13+(%) | 12 (48) | 43 (80) | 50 (85) | 27 (93) | 48 (94) | 48 (94) | <.001 |
| CD33−/CD13+(%) | 5 (20) | 8 (15) | 3 (5) | 0 (0) | 0 (0) | 1 (2) | <.001 |
| CD33+/CD13−(%) | 4 (16) | 4 (16) | 6 (10) | 2 (7) | 3 (6) | 2 (4) | <.001 |
| CD33−/CD13−(%) | 4 (16) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | <.001 |
Unless otherwise indicated, the values shown are the no. of positive cases, with the percentage in parentheses.
Abbreviation: NS, not significant.
All AML-M0 cases tested positive for αMPO.